Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026

Rhea-AI Summary

Curis (NASDAQ: CRIS) will report first quarter 2026 financial and operating results on May 12, 2026 at 4:00 p.m. ET and will host a conference call and simultaneous webcast the same day at 4:30 p.m. ET.

Dial-in numbers and a live audio webcast are available; a replay will be posted at www.curis.com.

AI-generated analysis. Not financial advice.

News Market Reaction – CRIS

+8.17%

2 alerts

+8.17% News Effect

+$2M Valuation Impact

$24.90M Market Cap

0.2x Rel. Volume

On the day this news was published, CRIS gained 8.17%, reflecting a notable positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $24.90M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Q1 2026 earnings call: 4:00–4:30 p.m. ET on May 12, 2026 Registered resale shares: 107,706,700 shares Cash balance: $5.1 million +5 more

8 metrics

Q1 2026 earnings call 4:00–4:30 p.m. ET on May 12, 2026 Timing for release and conference call/webcast

Registered resale shares 107,706,700 shares Shares registered on Form S-3 from Jan 2026 financing

Cash balance $5.1 million Cash and equivalents as of Dec 31, 2025 (Form 10-K)

PIPE net proceeds $18.6 million Net proceeds from January 2026 PIPE financing (Form 10-K)

Shares outstanding 39,978,693 shares Common shares outstanding as of Mar 20, 2026 (Form 10-K)

Nasdaq bid minimum $1.00 per share Minimum bid price under Nasdaq Listing Rule 5550(a)(2)

Days below minimum 30 consecutive business days Period with bid below $1.00 leading to delist letter

Insider purchase 10,000 shares at $0.5487 Open-market buy by director reported Apr 1, 2026

Market Reality Check

Price: $0.5236 Vol: Volume 174,743 vs 20-day ...

low vol

$0.5236 Last Close

Volume Volume 174,743 vs 20-day average 801,438 (relative volume 0.22) ahead of the earnings date notice. low

Technical Shares at $0.5702, trading below the $1.22 200-day MA and far under the $3.13 52-week high.

Peers on Argus

CRIS was at $0.5702 while peers were mixed: AKTX +2.29%, QTTB +1.98%, but ELEV -...

CRIS was at $0.5702 while peers were mixed: AKTX +2.29%, QTTB +1.98%, but ELEV -2.28%, FBLG -6.34%, GDTC -6.12%, indicating stock-specific factors rather than a unified sector move.

Common Catalyst Several biotech peers also had news, including an earnings release for Q32 Bio and a shareholder letter from FibroBiologics, reflecting ongoing news and earnings flow across the group.

Previous Conferences,earnings date Reports

1 past event · Latest: Mar 12 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Mar 12	Earnings date notice	Neutral	-5.9%	Announced timing for Q4 2025 results and related conference call.

Pattern Detected

Prior earnings-date scheduling news coincided with a negative price reaction, despite neutral content.

Recent Company History

Over the last six months, Curis has combined financing, clinical updates, and routine scheduling announcements. A prior notice on Mar 12, 2026 set the Q4 2025 earnings call timing and saw a -5.93% next-day move, suggesting that even neutral logistics updates can coincide with volatility. Today’s Q1 2026 earnings-date notice continues this pattern of pre-announcing result dates and conference-call logistics amid broader financing and clinical developments.

Historical Comparison

-5.9% avg move · Past earnings-date notices for CRIS saw an average move of -5.93%, indicating these scheduling updat...

conferences,earnings date

-5.9%

Average Historical Move conferences,earnings date

Past earnings-date notices for CRIS saw an average move of -5.93%, indicating these scheduling updates have coincided with notable volatility.

Curis has consistently pre-announced quarterly result dates and investor calls, maintaining a recurring communications pattern around earnings.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-02-13

An effective S-3 shelf dated Feb 13, 2026 registers 107,706,700 common shares for resale from a January 2026 financing. Curis receives no proceeds from investor resales but would receive cash if the associated warrants are exercised. The filing has 0 recorded usage events so far.

Market Pulse Summary

The stock moved +8.2% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +8.2% in the session following this news. A strong positive reaction aligns with the pattern that even logistical earnings-date news can coincide with meaningful moves; a prior notice on Mar 12, 2026 saw a -5.93% move. The existing S-3 registering 107,706,700 shares for resale and recent Nasdaq delisting risk underline financing and listing overhangs that could temper sustainability if optimism fades.

Key Terms

irak4, flt3

2 terms

irak4 medical

"an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced"

IRAK4 is a protein in immune-system cells that acts like a control knob for inflammation signals, helping the body detect and respond to infections. Drugs that block IRAK4 can dial down excessive inflammation, so IRAK4 is an important target for developing treatments for autoimmune diseases and some cancers; progress or setbacks in IRAK4 drug programs can materially affect the prospects and valuation of companies working in those areas.

flt3 medical

"an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced"

FLT3 is a gene that makes a protein acting like a growth switch for blood-forming stem cells; when that switch is faulty or overactive it can drive certain blood cancers, most notably acute myeloid leukemia. Investors care because drugs that target FLT3 mutations can become important therapies, influencing clinical trial outcomes, regulatory approvals and the future revenues and valuations of biotech companies—think of it as a key control knob whose position can determine a treatment’s market value.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEXINGTON, Mass., May 5, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its first quarter 2026 financial and operating results on Tuesday, May 12, 2026, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET.

Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can be accessed here or from the investor section of the Curis website. A replay of the conference call will be available at www.curis.com.

About Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 and FLT3 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor, ibrutinib, in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of emavusertib in combination with the BTK inhibitor, zanubrutinib, in chronic lymphocytic leukemia (CLL). The Company's monotherapy and combination studies in acute myeloid leukemia (AML) are substantially complete, with additional funding the Company plans to continue development of emavusertib in AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene Discovery Technologies Limited, has the exclusive license to emavusertib (CA-4948). For more information, visit Curis's website at www.curis.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-report-first-quarter-2026-financial-and-operating-results-and-host-conference-call-and-webcast-on-may-12-2026-302763278.html

SOURCE Curis, Inc.

FAQ

When will Curis (CRIS) release Q1 2026 financial results and hold the conference call?

Curis will release Q1 2026 results on May 12, 2026 at 4:00 p.m. ET. According to Curis, management will host a conference call and webcast the same day at 4:30 p.m. ET for investors and analysts.

How can I join the Curis (CRIS) May 12, 2026 conference call and webcast?

Dial in via (800)-836-8184 U.S. or (646)-357-8785 internationally, or access the live audio webcast. According to Curis, the webcast is available from the investor section of the company website.

Will Curis (CRIS) provide a replay of the May 12, 2026 earnings call and where is it posted?

Yes. A replay of the conference call will be available on the Curis website. According to Curis, the replay can be accessed at www.curis.com after the live event for later listening.

What topics will Curis (CRIS) likely cover during the Q1 2026 call on May 12?

The call will cover first quarter 2026 financial and operating results and related business updates. According to Curis, management will present results and provide an opportunity for investor questions during the webcast and call.

Where can investors find the Curis (CRIS) webcast link for the May 12, 2026 presentation?

Investors can find the live audio webcast link on the company's investor relations webpage. According to Curis, the webcast is accessible from the investor section of the Curis website at the scheduled time.